期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 55, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2021.128451
关键词
JAK1; JAK1 inhibitor; 4-(1; 5-triazole)-pyrrolopyrimidine; Molecular docking study; Kinase inhibitor
资金
- GIST Research Institute (GRI) IIBR grant - GIST in 2021
In this study, novel 4-(1,5or 2,5-triazole)-pyrrolopyrimidine derivatives with aromatic moieties were synthesized as JAK1 inhibitors, and an in vitro enzyme assay was used to evaluate the JAK inhibitory effects. Among these JAK1 inhibitors, compound 23a showed high JAK1 selectivity with a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.
JAK inhibitors have been considered as useful targets for the treatment of related diseases. However, firstgeneration JAK inhibitors have side effects such as anemia, thrombocytopenia, neutropenia and headaches which have been suggested to result from high JAK2 inhibition. Second-generation JAK inhibitors with more specific JAK isozyme inhibition have been studied to eliminate these adverse effects. In this study, novel 4-(1,5or 2,5-triazole)-pyrrolopyrimidine derivatives with aromatic moieties were synthesized as JAK1 inhibitors, and an in vitro enzyme assay was used to evaluate the JAK inhibitory effects. Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据